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Abstract 
Placebo analgesia (PA) is accompanied by decreased activity in pain-related brain regions, 
but also by greater prefrontal cortex (PFC) activation, which has been suggested to reflect increases in 
top-down cognitive control and regulation of pain. Here we test whether PA is associated with altered 
prefrontal monitoring functions that could adjust nociceptive processing to a mismatch between 
expected and experienced pain. We recorded event-related potentials to response errors in a go/nogo 
task during placebo vs. a matched control condition. Error commission was associated with two well-
described components, the error-related negativity (ERN) and the error positivity (Pe). Results show 
that the Pe, but not the ERN, was amplified during placebo analgesia compared to the control 
condition, with neural sources in the lateral and medial PFC. This Pe increase was driven by 
participants showing a placebo-induced change in pain tolerance, but was absent in the group of non-
responders. Our results shed new light on the possible functional mechanisms underlying PA, 
suggesting a placebo-induced transient change in prefrontal error monitoring and control functions.  
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Introduction 
Placebo analgesia (PA) refers to a reduced pain sensation due to the belief in an otherwise 
non-effective treatment [1,2]. During the last decade, advances have been made in understanding the 
neurophysiological mechanisms and psychological processes underlying the generation and 
maintenance of PA. Converging neuroimaging evidence demonstrates that placebo effects are 
accompanied by decreases of pain-related brain activation in the so-called ‘pain matrix’ [3,4,5,6]. 
Such decreases are consistently paralleled by increased activity in other regions, such as lateral and 
medial prefrontal cortex (LPFC and MPFC) – both during PA [3,4,7,8] and as early as during 
expectation of relief, before actual pain stimulation [4,6]. However, thus far there is no conclusive 
evidence regarding the functional role of these prefrontal areas in PA [9]. Several authors have 
suggested that LPFC activations during PA reflect a recruitment of cognitive control mechanisms that 
could in turn trigger opioidergic changes in the descending pain inhibitory system [e.g. 6,9,10,11,12].  
Here we address the question of whether PA could be intertwined with a key function of prefrontal 
cognitive control networks, namely error processing. 
In line with this hypothesis, previous research has shown that the expectation of pain relief is 
crucial for the implementation of the analgesic response [10]. In their seminal study, Wager et al. [6] 
reported enhanced activations in LPFC and MPFC, along with orbitofrontal regions during the 
anticipation of immediate pain administration under PA. Remarkably, brain activity in these cognitive 
control regions, including LPFC, MPFC, and parietal regions, predicted inter-individual differences in 
placebo responses [13]. Further, transient and reversible inhibition of LPFC by means of repetitive 
transcranial magnetic stimulation (rTMS) was found to prevent PA, suggesting a causal role of this 
cognitive control region for the implementation of placebo analgesia [12].  
We reasoned that the functional role of prefrontal cognitive control regions such as LPFC and 
MPFC during maintenance of PA may be related to the monitoring and the regulation of upcoming 
nociceptive input. During PA, the brain has to adjust to a mismatch between predicted pain and actual 
nociceptive input (i.e. a prediction error). PA may thus require two complementary processes, which 
are also crucial for error monitoring, and central to cognitive control in general [14,15,16]: first, PA 
probably requires monitoring of prediction errors between expected and actual nociceptive signals, 
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and second, subsequent adjustments in top-down control of neural processing (see Fig. 1). Strikingly, 
the specific brain regions showing enhanced activation during placebo analgesia, most notably medial 
and lateral PFC areas, were previously associated with these particular functions [e.g. 17]. Several 
influential theoretical accounts of cognitive control converge in their proposition that MPFC is crucial 
for the monitoring of conflicts, prediction errors, and other negative or at least surprising events that 
require adjustments in cognitive control [14,17,18,19,20,21,22]. The necessary subsequent 
adjustments in top-down control are thought to be implemented in more lateral prefrontal regions 
[14,17]. In light of this model, we reasoned that if the implementation of PA depends on the same 
prefrontal brain mechanisms as more general control processes, then PA may in turn also exert 
influences on error processing brain processes (see Fig. 1). 
Previous electrophysiological studies have identified event-related potentials (ERPs) 
specifically associated with early error detection. Response errors typically induce a large negative 
ERP component (termed the error-related negativity, or ERN) peaking within the first 100 ms 
following response onset over frontocentral scalp electrode positions [23,24]. It is commonly assumed 
that the ERN reflects an automatic conflict or prediction error signal generated in the MPFC 
[19,23,25,26]. The ERN is followed by the error positivity (Pe), a large positive deflection peaking 
between 100-300 ms with a more central scalp topography [27,28,29,30]. The Pe appears to be 
generated by similar MPFC regions as the ERN, as well as additional sources, including the LPFC, 
insula, and orbitofrontal cortex [31,32]. ERN and Pe are often found to be functionally dissociated 
[28]. Whereas the ERN is thought to reflect a generic error/conflict detection process based on 
internal motor representations [14,19,33], the functional significance of the Pe is related to more 
elaborate stages of error processing, including subsequent adjustments in behavioral control and 
awareness of error commission [27,28,33,34,35,36]. 
If the assumption holds true that PA is based on cognitive mechanisms that functionally 
overlap with cognitive control processes related to conflict monitoring, one would expect PA to have 
a direct influence on such electrophysiological markers of error processing. The goal of our study was 
to test whether PA may be associated with specific changes in the aforementioned monitoring 
processes. On the one hand, one may hypothesize that PA may decrease error-related brain responses, 
5 
as they are generated by mediofrontal mechanisms that may also be sensitive to negative affect, pain, 
and –more generally– need for control [21]. Yet, it has been shown that the effects of PA are usually 
quite selective regarding the specific instructions about the treatment effects. For example, only the 
hand upon which “analgesic” cream is applied showed reduced pain sensitivity and was associated 
with reduced ACC activity, but not so for the opposing hand [6]. Therefore, it appears unlikely that 
PA reduces negative affect in general – unless participants were directly instructed that this is what 
the treatment does [see e.g. 37]. 
Alternatively, we predict that PA amplifies error-related brain potentials during the 
expectation of analgesic effects. This hypothesis is based on accumulating evidence showing that 
increased activity in medial and lateral prefrontal areas, which are crucial for cognitive control and 
regulation of emotion, is predictive for the installation of analgesic effects [6,9,10,12,13]. 
Participants were tested using a randomized cross-over within-subject design. They were led 
to believe that a single (inert) dose of a capsule ingested at the beginning of the experiment was either 
a reliable painkiller (placebo condition) or an ineffective pill (control condition). Pain threshold and 
tolerance were measured at the beginning and at the end of each experimental session to quantify the 
individual placebo response to a standard thermal pain administration on the forearm. During the 
experimental session, 64-channel EEG was recorded while participants performed a speeded go/nogo 
task and occasionally committed unwanted response errors (i.e. false alarms on nogo stimuli). This 
enabled us to characterize error-related brain activities during PA versus a perfectly matched control 
condition, using a within-subject design. Based on the hypothesis that common brain areas underlie 
both PA and error monitoring (see Fig. 1), we predicted that PA would have an amplifying effect on 
these ERP components specifically related to error detection.  
 
Materials and Methods 
Participants 
Twenty healthy undergraduates from Ghent University (14 women; all right-handed as 
determined by self-report; mean age 21.2 years; range 18-31) participated in two experimental 
sessions (placebo and control), both taking place at the same time on two consecutive days. Session 
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order was counterbalanced across participants. In order to enhance the plausibility of the cover story, 
the experimenter was wearing a white medical coat and conducted a brief interview at the beginning 
of the first session, in which participants were thoroughly screened for any history of serious physical, 
mental, or neurological illness, for pain-related disorders, allergies, and current medication. Two 
female participants had to be excluded from the analysis, one because she did not believe in the cover 
story used to induce PA, and another for reporting that she did not experience any temperature 
increase during thermal pain stimulation. Accordingly, the final sample contained 18 naïve 
participants. The study was conducted in accordance with the Declaration of Helsinki and approved 
by the ethics committee of the Faculty of Psychological and Educational Sciences, Ghent University. 
All participants gave informed written consent, and were compensated 40€. 
Stimuli and Task 
The speeded go/nogo task used in our study has been extensively described elsewhere 
[29,30,32,38,39]. Each trial started with a central fixation cross (presented for 1s) followed by a black 
arrow that changed color after a randomly jittered interval of 1-2s. In two thirds of the trials (go-
trials), the arrow turned green, indicating that participants should respond as quickly as possible by 
pressing the space bar. In the remaining third of trials (nogo), the arrow turned either cyan (instead of 
green) or turned green, but changed direction (relative to the black arrow), indicating participants had 
to withhold their response. One second after the response, feedback was given in the form of an 
isoluminant green or red dot for correct versus incorrect responses, respectively. In order to increase 
commission errors, only fast responses, as determined by calibrating an individual RT limit updated 
on a trial-by-trial basis [29,30] were classified as correct. This imposed speed pressure promoted the 
occurrence of many responses errors, allowing for reliable error-related ERP waveforms in each 
condition. Each of the six blocks consisted of 60 trials (40 go and 20 nogo), resulting in 360 trials in 
total (~ 30 min). 
Apparatus 
Painful thermal stimulation and threshold tests were administered using a MSA Thermotest 
device (SOMEDIC Sales AB, Sweden), with the thermode placed on the left or right volar forearm, 
and controlled using the manufacturer’s software. The experiment took place in an 
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electromagnetically shielded, dimly lit chamber, with participants seated 80cm in front of a computer 
screen. Stimulus presentation was controlled using E-Prime 2.0 software. 
Procedure and measures 
Placebo induction. Volunteers were told they were taking part in a study investigating the 
effects of a widely used painkiller on EEG activity during an “attention task.” Prior to the experiment, 
participants read an information sheet about the medication, its analgesic properties (“highly effective 
in reducing pain on many body parts, including heat pain”), the onset (“about 11 minutes after oral 
administration”), and duration (“2-4 hours”) of these effects. Following the first pain threshold 
measurement, participants were given a capsule containing 160 mg of Mannitol (a medically non-
effective white sugar substitute) and a glass of water. They were given instructions aimed at inducing 
either an analgesic placebo or a neutral effect: “This is a capsule of an effective pain reliever. In 10-15 
minutes the medication will be fully effective, and notably decrease your sensitivity to the thermal 
heat pain” (Placebo condition) or “This is a capsule without any effective drug, needed as a control. It 
will not decrease your sensation of pain nor induce any other effects” (Control condition). 
Measurement of pain sensitivity. Pain tolerances and thresholds were determined at three 
intervals during each session (see Fig. 2A): Prior to intake of the Mannitol capsule (T1, corresponding 
to the baseline); after installing the EEG cap and electrodes (~ 20 minutes after intake), in order to 
establish the placebo belief (T2); and directly after the go/nogo task (T3, as a manipulation check). 
Thresholds were assessed by applying a steadily increasing thermal stimulation (starting at 32°C, with 
a slope of 2°C/s) to the inner wrist. On four consecutive trials (with 5s breaks between trials), 
participants were instructed to press a button in order to cease the thermal stimulation, thereby 
terminating the trial, at the moment the sensation changed from that of heat to pain (pain threshold 
measure). In a further four trials, participants were requested to button press to indicate the point at 
which the pain became unbearable (pain tolerance measure). For each time point, both pain threshold 
and pain tolerance were calculated as the average temperature across the four trials. The net placebo 
effect upon threshold and tolerance was quantified as the difference between the differences 
(interaction term) of the temperatures in T3 versus T1 between placebo and control condition (T1Placebo 
-T3 Placebo)-(T1 Control -T3 Control). Participants did not receive feedback as to temperature values. 
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However, in order to enhance the placebo induction, following the second threshold measurements 
(T2) participants were told (irrespective of the actual values): “Both your pain threshold and your pain 
tolerance have significantly increased.” (Placebo condition) or “Your threshold are very similar to the 
ones obtained in the first test.” (Control condition). 
Further, two single-pulse thermal stimulations, lasting 5s, were administered at three time 
points for each session. Participants were informed that this stimulation served to determine 
subjective changes in pain intensity throughout the experiment, and were asked to rate the pain 
intensity of the pulse on a scale of 0-8, with 0 being no pain, and 8 being the greatest pain imaginable. 
The single-pulse stimulations were administered directly after the threshold and tolerance 
measurements for T1, but directly before measurement for T2 and T3. In all cases but one, the pulse 
stimulation was identical to the T1 threshold and tolerance averages; unbeknownst to the participants, 
we lowered the single-pulse threshold and tolerance temperatures by 1.5°C in the placebo condition at 
T2 (immediately before the go/nogo task) in order to mimic a genuine analgesic effect of the 
administered pill [6].  
In order to assess belief in the placebo manipulation, participants indicated their expectancy 
of the analgesic effect of the pill they ingested following each experimental session in a questionnaire. 
They responded to the item “Did you expect an effect of the capsule intake on your pain sensitivity?” 
on a Likert-scale from 1 to 7 (Analgesia expectancy). To check for the presence of a subjectively 
experienced analgesic effect, we asked: “How efficient was the capsule in reducing the pain sensation 
when you received thermal pain?”  After the second experimental session, all participants were 
thoroughly debriefed and screened for possible suspicion concerning the credibility of the cover story. 
Additional Behavioral Measures 
To control whether potential effects were mediated by mood changes or by other beliefs 
participants might have, we measured state anxiety at the end of each EEG session using the validated 
Dutch version of the STAI [40], and included two items at the end of the second session concerning 
the expectancy of medication-related cognitive performance increase and decrease (“Did you expect 
an improvement of your performance in the attention task, following the intake of the pain medication 
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capsule?” and  “Did you expect a decrease in your performance in the attention task, following the 
intake of the pain medication capsule?”). 
EEG preprocessing and analyses 
EEG was recorded from 64 electrodes with a sampling rate of 2048 Hz (ActiveTwo Biosemi 
system). Following standard practice, raw data were re-referenced offline to a common average and 
filtered (0.5-30 Hz, and 50 Hz notch). Following ocular correction using an ICA algorithm as 
implemented in Brain Vision Analyzer 2.0 software, the data was segmented from -500 to 1000 ms 
around responses, separately for fast correct hits and commission errors. Segments exceeding 
amplitudes of ±80µV were excluded prior to baseline correction and averaging. Individual average 
ERP waveforms were filtered using 1-30 Hz. 
In order to assess the time windows of error-related components in a unbiased and objective, 
data-driven way, we first calculated the grand average ERP waveform for errors across both placebo 
and control condition and identified the ERN and Pe components based on two reference-free global 
measures of the electric field, dissimilarity and global field power (GFP) [41]. GFP measures the 
overall “energy” of the electrical field on the scalp, by summing up the squared field potentials across 
all electrodes. Conversely, dissimilarity measures the change in the topographical distribution 
(irrespective of changes in the local or global strength of the ERP signal), and is therefore highly 
sensitive to transitions between different microstates or ERP components [41,42,43,44]. ERN and Pe 
were identified as phases of high global field power, between local maxima of topographical 
dissimilarity [41,42,43,44]. Thus, we extracted the ERN amplitude as the minimum value between -40 
and 60 ms around response, and the Pe as the maximum between 100-280 ms, for errors and fast hits 
separately in the two experimental conditions (placebo versus control), at the electrode sites Fz, FCz, 
and Cz, where these two error-related components were found to be maximal. Slow hits were not 
further analyzed, as they are characterized by different RT distributions compared to fast hits or errors 
[29,30]. 
Source analysis 
We used standardized low resolution brain electromagnetic tomography (sLORETA) [45] to 
estimate the neural generators underlying the increased Pe amplitude in the placebo condition (see 
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results below). In order to deal with the inverse solution problem and restrict the number of possible 
solutions, sLORETA assumes maximal “smoothness” of the current density, and further restricts the 
possible three-dimensional solutions to 6239 points in the cortical grey matter volume. With a 
regularization parameter of SNR = 10, source activity was first estimated for the individual ERPs, 
separately for fast hits and error trials in the placebo versus the control condition.  
Statistical analyses 
Behavioral and ERP data were analyzed by means of repeated-measures ANOVAs or mixed-
effects ANOVAs for group comparisons (placebo responders versus non-responders). Planned 
pairwise t-tests were Bonferroni-corrected for multiple comparisons. Statistically significant 
differences in the source space (sLORETA analysis) were evidenced using paired t-tests (uncorrected 
for multiple comparisons, given the smoothness of source activity estimation) performed on the mean 
activity from 100 to 280 ms after response onset (encompassing the Pe component). 
 
Results 
Behavioral 
Manipulation check. Questionnaire results revealed a strong effect of placebo versus control 
condition on analgesia expectation (Placebo mean = 4.61, SD = 1.69, Control mean = 1.33, 
SD = 0.77; t(17) = 8.1, p < 0.001) and on subjectively experienced pain relief (Placebo mean 4.44, 
SD = 1.04, Control mean = 1.44, SD = 0.51; t(17) = 13.1, p < 0.001), confirming that participants 
experienced a subjective pain-relieving effect of the capsule in the placebo compared to the control 
session.  
Changes in subjective pain intensity ratings (Likert scale 0-8) for the threshold temperature 
were tested using a repeated-measures ANOVA with the factors TIME (baseline T1 vs. T3) and 
CONDITION (placebo vs. control). We found a significant main effect for TIME (F(1,17) = 8.6, 
p = 0.008), but no significant main effect for CONDITION, and no significant interaction. The same 
statistical analysis run on the ratings obtained for the tolerance temperature revealed no main effect of 
CONDITION, but trends for the main effect of TIME (F(1,17) = 4.1, p = 0.059), as well as for the 
TIME x CONDITION interaction (F(1,17) = 4.1, p = 0.058). This latter interaction was driven by a 
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significant increase in pain intensity ratings at T3 compared to T1 in the control condition 
(Bonferroni-corrected t-test, p = 0.011), which was not present for the placebo condition (p = 1.00). 
The direction of the interaction effect was thus in accord with the prediction of analgesic effects 
following placebo beliefs. 
Further, we tested whether effects of PA could be supported in direct and more implicit 
measures of pain sensitivity, namely via changes in pain threshold and pain tolerance temperatures 
(see Fig 2B). Whereas a main effect for TIME was found for both pain threshold (F(1,17) = 9.2, 
p = 0.026) and pain tolerance temperature (F(1,17) = 10.1, p = 0.006), the interaction CONDITION x 
TIME yielded a trend only for the pain tolerance (F(1,17) = 4.0, p = 0.061), with no significant effect 
for the threshold (F(1,17) = 1.3, p = 0.28). Planned comparisons with Bonferroni-corrected t-tests 
confirmed that the difference between T3 and T1 (baseline) pain tolerance was significant only in the 
placebo condition (p = 0.005), but not in the control condition (p = 1.0), in line with our hypothesis. 
We note that, in accordance with previous studies on placebo effects [13], our sample contained 
substantial inter-individual variability regarding placebo responsiveness. We found that only 10 out of 
18 participants actually showed a differential increase of pain tolerance temperature (> 0.5°C) in the 
placebo compared to the control condition.  
Performance during the go/nogo task and other measures. The distribution of, and mean 
RTs for errors, correct fast hits, and correct slow hits did not significantly differ between placebo and 
control conditions (see Table 1), indicating a very similar performance across conditions. We did not 
observe a significant difference in levels of state anxiety between the two sessions, as measured with 
the STAI (placebo 40.8 versus control 42.1, t(17) = 1.3, p = 0.22). 
Error-Related ERPs 
Grand average event-related waveforms are depicted in Figure 3A. A repeated measures 
ANOVA including the within-subject factors RESPONSE (errors versus correct hits) and 
CONDITION (placebo versus control), carried out on the ERN amplitudes averaged across the three 
frontocentral electrodes (Fz, FCz, and Cz), revealed a highly significant main effect of RESPONSE 
(F(1,17) = 25.0, p < 0.001), showing, as expected, a larger ERN for errors relative to fast hits. 
However, the interaction term was not significant F(1,17) = 1.6, p = 0.23), suggesting that this early 
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error-related activity was not significantly influenced by PA. Further, the ERN did not significantly 
correlate with changes in pain tolerance (r = 0.11, p = 0.66), and was not different between placebo 
responders versus non-responders (GROUP x RESPONSE x CONDITION interaction, F(1,16) = 1.9, 
p = 0.18). 
A different statistical outcome was found for the Pe component. As expected, the mean Pe 
amplitude was also significantly larger for errors than correct hits (F(1,17) = 44.9, p < 0.001), but 
critically, this error-specific component was also modulated by PA, as evidenced by a significant 
RESPONSE x CONDITION interaction (F(1,17) = 7.0, p = 0.017). Planned comparisons using 
Bonferroni corrected t-tests showed that Pe amplitudes were larger for errors under placebo compared 
to control condition (p = 0.004), whereas no difference was seen for amplitudes in response to fast hits 
(p = 1.0), confirming that PA influenced error monitoring selectively. 
To further investigate whether this enhanced Pe amplitude was related to inter-individual 
differences in the placebo response, we compared Pe amplitudes between the two sessions, separately 
for the placebo-responders versus non-responders (see Figure 3B). The interaction effect between 
CONDITION and GROUP was significant (F(1,16) = 4.7, p = 0.045), demonstrating that the Pe 
amplitude significantly increased for the placebo condition in the responders (Bonferroni-corrected t-
test, p = 0.014), but not in the non-responders (p = 1.0). Further, individual differences in placebo 
response (tolerance increase) correlated positively with the Pe-amplitude effect (Spearman’s 
Rho = 0.46, p = 0.055). 
Source Reconstructions 
In order to gain insight into the brain generators underlying the modulation of the Pe 
component with PA, we used sLORETA to investigate which brain regions showed a significant 
interaction effect between RESPONSE x CONDITION around the Pe component (100-280 ms). This 
statistical source analysis revealed three clusters with higher error-specific activity during the placebo 
condition, localized in the MPFC (MNI peak coordinates x = 20, y = 35, z = 30), left LPFC (x = -15, 
y = 50, z = 45), and right LPFC (x = 45, y = 30, z = 25, see Table 2 for detailed results). In each of 
these three regions, we found significantly higher activation for the placebo than the control 
condition, specifically for error trials (see Figure 4). 
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Discussion 
Placebo effects are a compelling example of how perception may be profoundly shaped by 
expectations and social instructions, and more specifically how the generation and maintenance of 
beliefs in a pain-relieving treatment may regulate painful experiences. Despite a growing number of 
studies looking at the neural and pharmacological mechanisms, as well as psychological processes 
underlying this fascinating effect, little is known about the potential functional contribution of 
prefrontal cognitive control areas during PA. Previous studies have demonstrated that prefrontal areas 
(especially DLPFC and MPFC) are crucial for the installation of the analgesic response [3,12,13], but 
so far their functional role in PA remains unclear [cf. 9]. In order to test the assumption that PA could 
involve a recruitment of mechanisms similar to those employed in error monitoring, we compared 
error-related ERPs during PA versus a properly matched control condition, using a cross-over within-
subject design. 
Our results demonstrate for the first time that PA is related to altered error monitoring brain 
processes at the level of the Pe component. Importantly, additional analyses confirmed that this PA-
dependent effect upon the Pe was primarily driven by those participants who actually showed a 
placebo effect (increased pain tolerance), providing additional evidence that the Pe increase was 
linked to the analgesic effect of our manipulation. Remarkably, source reconstructions obtained using 
sLORETA confirmed that this effect was likely caused by increased activation of specific medial 
frontal as well as lateral prefrontal regions, which have classically been associated with adaptive 
control brain mechanisms [14,17] and more recently with adjustments to social norms and 
expectations [46,47,48,49], but have also been demonstrated to be crucial for PA [3,6,12,13]. 
Further, the ERP results suggest that the effects of PA are error-specific. Whereas the 
processing of correct actions (i.e. fast hits) was not influenced, neurophysiological responses to 
response errors were modulated by PA. Moreover, only the Pe component, and not the preceding 
ERN component, was reliably enhanced during PA. An additional analysis, in which we directly 
compared the GFP peaks of these two components [cf. 50] did not yield a significant interaction effect 
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between component (i.e. ERN versus Pe) and experimental condition. Hence, we cannot exclude the 
possibility that PA might also influence conflict or error processing at the level of the ERN. Whereas 
the ERN probably indexes an initial automatic stage of prediction error or motor mismatch detection 
in dMFC [14,19,35,51], the Pe has been related to later stages of error processing, leading to error 
awareness and subsequent adaptive changes in behavior [28,32,35]. Consistent with this framework, it 
has been argued that the Pe component reflects context updating, thus swiftly signaling error salience 
and the need for adjustments in cognitive control [27,28,36]. Accordingly, our novel results of a Pe- 
effect suggest that PA may induce a transient change in the reactivity of cognitive control networks. 
These networks are probably necessary in order to adjust to a mismatch between predicted and 
experienced pain (see Fig. 1) [52], to modulate nociception by top-down reappraisal, and to influence 
opioidergic antinociceptive pathways [6,11,12,53]. This transient increase in top-down cognitive 
control mechanisms could be general enough to modulate the processing of other events requiring 
enhanced cognitive control and top-down regulatory adjustments, such as response errors. Our 
findings also indirectly suggest that PA may depend on an altered balance between top-down 
expectations and bottom-up nociceptive processing. In line with this reasoning, a recent study [54] 
demonstrated that individual differences in a cognitive style of biases towards prior expectations were 
related to differences in placebo responsiveness. Furthermore, we also note the tight overlap between 
the source reconstructions underlying the Pe effect in LPFC and previous fMRI activations found in 
the exact same regions that actually predicted inter-individual differences in placebo responsiveness 
[6,13]. 
These changes in cognitive control processes during PA may be relatively specific to 
adjustments following mismatch detection, or alternatively, to events requiring emotion regulation 
[13]: A recent study combined placebo expectation with a working memory task in order to test 
directly whether PA interferes with executive attention resources [9]. Results showed additive, not 
interacting, effects of working memory load and placebo expectation on analgesia, suggesting that 
executive functions recruited during working memory are probably not directly involved in 
maintaining PA [9]. Consistent with this study, we did not find any differences in behavioral 
performance during placebo compared to the control condition. On the other hand, the use of an 
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adaptive response deadline might have prevented strong differences in behavioral indices of 
performance monitoring across the two conditions. However, this procedure was an important 
prerequisite in order to obtain a balanced number of errors (and hence ERP averages) between 
sessions. More generally, it is also conceivable that the PA-dependent Pe increase seen here indicates 
differences in affective error appraisal [35,36], rather than adjustments in attention or effort. This 
interpretation would be in line with the notion that PA is mediated by brain regions involved in the 
regulation of emotion [13]. 
Our results, showing a modulation of error monitoring by expectation of pain relief, add to 
accumulating evidence of the importance of prefrontal control mechanisms for placebo effects. To the 
best of our knowledge, the present ERP results give a first hint on their functional role: PA may in 
part depend on domain-general cognitive control mechanisms that subsume error processing, 
mismatch detection, and subsequent adjustments in cognitive and emotional control (see Fig. 1). 
Future studies are needed to investigate whether the modulation of adaptive control functions induced 
by PA could also be observed in emotion regulation or conflict-resolution tasks other than error 
monitoring, and to characterize the role of individual and social expectations in PA. 
Further, more research is needed to establish whether the observed link between error 
monitoring and placebo analgesia can also be shown in a more general population or alternatively in 
clinical settings, where pain experience or relief expectations may be altered. Given the relatively low 
spatial resolution of electrophysiological source estimation and the use of conventional (uncorrected) 
statistical thresholds in our sLORETA analysis, we also suggest that future studies should employ 
fMRI (ideally in combination with scalp EEG measurements) in order to investigate the 
neuroanatomical substrates of PA-mediated effects on error monitoring processes in more detail. 
These findings also underscore the malleability of early error and performance monitoring 
brain processes. They show that these mechanisms are not only influenced by trait-like emotional or 
motivational factors [39,55], but also by contextual or state-dependent changes in expectancies or 
beliefs. Psychosocial contextual factors such as expectation of pain relief may impose powerful 
modulations upon prefrontal cognitive control networks. As such, our results suggest that beyond 
environmental, genetic, or neuroanatomical differences, cognitive control and error monitoring brain 
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processes are also readily shaped by intra-individual variations concerning abstract beliefs or social 
expectations. 
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Figure Captions 
 
Fig. 1 – Conceptualizing placebo analgesia (PA) and error monitoring (EM) in a common 
cognitive control framework. Both EM and PA require the detection of conflicts or prediction errors, 
and subsequent adjustments in cognitive processing. Thus, they could be based on similar prefrontal 
functional mechanisms and interact with each other.  
 
Fig. 2 – Experimental design. Measures of pain sensitivity were obtained at baseline just prior 
to placebo capsule administration (T1), 15 min after capsule intake in order to enhance placebo beliefs 
(T2), and at the end of the experiment, following the go/no-go task (T3), in order to measure the 
individual placebo response (A). Average change in pain sensitivity, as measured by pain threshold 
and pain tolerance increases, comparing T3 to T1 baseline (B). Vertical bars denote standard errors. 
 
Fig. 3 – Grand average ERPs for errors and correct hits in placebo and control conditions at 
electrode FCz (A). Pe amplitudes (mean across Fz, FCz, and Cz) for placebo responders and non-
responders separately, for placebo and control sessions. Only placebo-responders showed an increased 
Pe response to errors in the placebo condition (B). Vertical bars denote standard errors.  
 
Fig. 4 – sLORETA source estimations for the statistical interaction effect [PLACEBO 
ERRORS > PLACEBO HITS] > [CONTROL ERRORS > CONTROL HITS] on the Pe component, 
100-280 ms after response (p < 0.05 uncorr.) (A). Time courses of the three ROIs for errors and hits in 
both placebo and control conditions (B). 
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Tables 
Table 1 – Behavioral results. Means and standard deviations (SD) of trial numbers and RTs 
for the different response conditions in the two experimental sessions (Placebo versus Control). None 
of these mean numbers differed significantly between conditions. 
 Number of trials - Mean (+1SD) Reaction times - Mean (+1SD) 
 Placebo Control Placebo Control 
Fast Hits 82.1 (18.4) 83.1 (16.1) 232.1 (30.2) 234.6 (22.7) 
Slow Hits 155.8 (18.8) 153.8 (16.6) 315.3 (22.9) 322.9 (21.8) 
Errors 46.1 (21.3) 49.2 (18.7) 250.4 (30.0) 255.7 (22.2) 
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Table 2 – Results of the sLORETA source estimation for the contrast [Placebo 
Errors > Placebo Hits] > [Control Errors > Control Hits] during the time window of the scalp Pe 
effect, 100-280 ms following the response. All activations are thresholded at p < 0.05 (uncorrected). 
Region Lat Max t-value 
MNI-coordinates Number of 
voxels x y z 
Cingulate gyrus R/L 2.10 15 25 40 4 
Medial frontal gyrus R/L 2.33 20 35 30 47 
Inferior frontal gyrus R 2.48 50 25 25 7 
Middle frontal gyrus R 2.78 45 30 25 66 
Precentral gyrus R 2.33 35 -5 40 25 
Postcentral gyrus R 2.15 40 -25 40 3 
Subgyral R 2.23 35 -5 45 4 
Superior frontal gyrus R 2.69 40 35 35 37 
Middle frontal gyrus L 2.11 -30 35 35 12 
Superior frontal gyrus L 2.28 -15 50 45 16 
Precuneus L 2.09 -15 -60 25 3 
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